However, we did find that blocking the AKT, ERK, or BTK signaling pathways in primary CLL cells reduced MSI2 protein levels, indicating that multiple signaling pathways control MSI2 expression. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.